 CAMBRIDGE, Mass. MONTREAL--BUSINESS WIRE--Repare Therapeutics Inc. Repare or the Company Nasdaq: RPTX, a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the first quarter ended March 31, 2021. We have advanced the Phase 12 clinical development of our ATR inhibitor RP-3500, with initial results expected from the monotherapy arm of th 